EUVIMEDEUVIMED entdecken
Crossref

2820-LB: Durability of Glycemic Improvement With and After GLP-1 Therapy in a Real-World Remote Monitoring Diabetes Program (RMDP)

ROBERTA A. JAMES, WEI LU, CHRISTA-MARIE SINGLETON

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2820-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ROBERTA A. JAMES und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: A recent systematic review of randomized trials reported clinically meaningful metabolic rebound following GLP-1 RA discontinuation, 0.58% TD1 and 0.65% TD2, with greater worsening over longer follow-up. However, the durability of glycemic improvement after discontinuation in real-world settings is not well understood. This study examined the impact of GLP-1 use on glycemic improvement and sustainability after discontinuation within an RMDP.

Methods

We conducted a retrospective cohort analysis of adults (≥18 years) enrolled in Teladoc Health's RMDP on or after January 1, 2022, with up to 24 months of follow-up and started the program uncontrolled (A1c>= 7%). Outcomes were stratified by 12-month GLP-1 adherence using proportion of days covered (adherent: PDC ≥0.8 vs nonadherent: <0.8) and compared with members without observed GLP-1 use. Estimated A1c (eA1c) reduction calculated via Nathan’s method were age adjusted. A one-sample t-test evaluated eA1c change among members adherent to GLP-1s for 12 months who discontinued therapy for the next 12 months.

Results

The cohort included 10,654 members (45.4% female; mean age 60.9±10.5 years); 47.8% used GLP-1s during the first year, of whom 76.3% were adherent. Baseline A1cs were 8.9%, 9.0%, and 8.6% for the groups, respectively. Adjusted mean eA1c reduction at 24 months was greatest in the GLP-1 adherent group (−2.6%; SD 2.4%), compared with nonadherent GLP-1 users (−1.8%; 2.6%) and non-GLP-1 users (−1.1%; 2.3%). Among adherent members, 2.5% discontinued GLP-1 therapy after 12 months with a mean difference in A1c reduction at 24 months from 12 months of 0.10%, p-value = 0.43.

Conclusion

GLP-1 adherence had greater long-term eA1c reduction than nonadherent and non-GLP-1 users. Members who discontinued GLP-1 therapy after sustained adherence did not experience significant glycemic rebound over 12 months. These findings suggest that RMDPs may support durable glycemic improvement though more study is required. Disclosure R.A. James: Employee; Current; Teladoc Health. Stock/Shareholder; Current; Teladoc Health. W. Lu: Employee; Current; Teladoc Health. C. Singleton: Employee; Current; Teladoc Health.

Zitieren

APA

JAMES, R. A., LU, W., & SINGLETON, C. (2026). 2820-LB: Durability of Glycemic Improvement With and After GLP-1 Therapy in a Real-World Remote Monitoring Diabetes Program (RMDP). Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2820-lb

Vancouver

JAMES RA, LU W, SINGLETON C. 2820-LB: Durability of Glycemic Improvement With and After GLP-1 Therapy in a Real-World Remote Monitoring Diabetes Program (RMDP). Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2820-lb

BibTeX
@article{JAMES2026,
  author = {JAMES, ROBERTA A. and LU, WEI and SINGLETON, CHRISTA-MARIE},
  title = {2820-LB: Durability of Glycemic Improvement With and After GLP-1 Therapy in a Real-World Remote Monitoring Diabetes Program (RMDP)},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2820-lb}
}
Kostenlos starten →